The longer the gap in treatment, the bigger the jump in risk up to a 22% increase for heart attack, stroke and death after two years off GLP-1s, largely erasing the cardiovascular benefits gained during treatment
Track the week, not just the weight
Third-party testing provides assurance that the product contains what's on the label
Retrovirology 18 , 13 (2021)
Recommended Dietary Allowances: 10th Edition
Figure 2: Changes in body weight from baseline to the end of treatment at week 26 associated with the treatment policy estimand, in the randomly assigned treatment groups administered either 0.3 mg of cagrilintide, 0.6 mg of cagrilintide, 1.2 mg of cagrilintide, 2.5 mg of cagrilintide, 4.5 mg of cagrilintide, 3.0 mg of liraglutide, or a placebo